Business
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent operational updates.
About this update from Adc Therapeutics Sa
[{"type":"text","content":"Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025","length":191,"tagName":"p","attribs":{}},{"type":"text","content":"Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients with 2L+ DLBCL; data update anticipated in late 2025 once PFS events reached ","length":174,"tagName":"p","attribs":{}},{"type":"text","content":"$250.9M in cash as of December 31, 2024, provides runway expected to fund operations into the second half of 2026","length":113,"tagName":"p","attribs":{}},{"type":"text","content":"Company to host conference call today at 8:30 a.m. EDT","length":54,"tagName":"p","attribs":{}},{"type":"text","content":"LAUSANNE, Switzerland, March 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent operational updates.","length":317,"tagName":"p"},{"type":"image","alt":"ADC Therapeutics logo (PRNewsfoto/ADC Therapeutics SA)","displaySize":"","headline":null,"caption":"ADC Therapeutics logo (PRNewsfoto/ADC Therapeutics SA)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":250,"url":"https://media.zenfs.com/en/prnewswire.com/b45d5be0d129d2f2b168ba1839a068c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xnw4DzeStakBHZIZhIV_hA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ0MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b45d5be0d129d2f2b168ba1839a068c7","width":400,"height":250}},"href":"https://mma.prnewswire.com/media/2543351/ADC_Therapeutics_SA__logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We achieved several key milestones in 2024, advancing our expansion trials with ZYNLONTA® in combinations and in earlier lines of DLBCL therapy, progressing our early research solid tumor program to the IND-enabling stage and reducing operational spend while at the same time strengthening the balance sheet," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "We closed the year by fully enrolling our confirmatory LOTIS-5 DLBCL study, reported encouraging in...